论文部分内容阅读
目的:观察芩丹胶囊对自发性高血压大鼠(spontaneous hypertensive rat,SHR)的降压作用和对血浆内皮素(ET)、降钙素基因相关肽(CGRP)、血浆和血管组织中血管紧张素II(Ang-II)含量的影响,并探讨可能的降压机制。方法:将40只SHR均分为5组:芩丹胶囊大剂量组、小剂量组、牛黄降压胶囊组、卡托普利组和模型组,8只Wistar-Kyoto(WKY)大鼠作为正常对照组,分别给予相应药物;给药12周后观测各组大鼠血压、血浆ET、CGRP及血浆和肠系膜动脉组织中Ang-II的含量。结果:芩丹胶囊大剂量组血压较模型组血压明显降低(P<0.01),与牛黄降压胶囊组和卡托普利组相比差异无统计学意义(P均>0.05);与模型组相比,芩丹胶囊大剂量能够降低SHR血浆ET含量,升高CGRP含量(P均<0.05),且效果优于牛黄降压胶囊和卡托普利;对血浆Ang-II含量无影响(P>0.05),且能够降低肠系膜血管组织中Ang-II含量(P<0.05)。结论:芩丹胶囊对SHR具有良好的降压作用,其机制可能与对血浆中血管活性肽和局部肾素-血管紧张素系统(RAS)的调节有关。
Objective: To observe the antihypertensive effect of Qidan Capsule on spontaneous hypertension rats (SHR) and plasma ET, calcitonin gene-related peptide (CGRP), and vascular tone in plasma and vascular tissues. The effect of Ang-II content and explore possible hypotensive mechanisms. Methods: 40 SHRs were divided into 5 groups: Qidan capsule high-dose group, small-dose group, Niuhuang Jiangya capsule group, captopril group and model group, 8 Wistar-Kyoto (WKY) rats as normal The control group were given the corresponding drugs; after 12 weeks of administration, blood pressure, plasma ET, CGRP, and plasma and mesenteric arterial tissue Ang-II levels were observed in each group. RESULTS: Compared with the model group, the blood pressure of the Qidan capsule high-dose group was significantly lower (P<0.01), and there was no significant difference between the Niuhuang Jiangya capsule group and the captopril group (P>0.05); In comparison, the large dose of Qidan capsule can reduce plasma ET levels in SHR and increase CGRP content (P<0.05), and the effect is better than Niuhuang Jiangya capsule and captopril; it has no effect on plasma Ang-II content (P >0.05), and can reduce the Ang-II content in mesenteric vascular tissue (P<0.05). Conclusion: Qidan Capsule has a good antihypertensive effect on SHR, and its mechanism may be related to the regulation of plasma vasoactive peptides and local renin-angiotensin system (RAS).